![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
High Rate of Sustained Virologic Response With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) Plus Sofosbuvir (Nucleotide NS5B Inhibitor), With or Without Ribavirin, in Treatment-Naive Patients Chronically Infected With HCV GT 1, 2, or 3
|
|
|
Reported by Jules Levin
AASLD
Nov 9-13 2012 Boston
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Eley T, Wind-Rotolo M, Huang S-P, Gao M,McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, andGrasela DM for the AI444040 Study Group
![AASLD1.gif](../images/111312/111312-6/AASLD1.gif)
![AASLD2.gif](../images/111312/111312-6/AASLD2.gif)
![AASLD3.gif](../images/111312/111312-6/AASLD3.gif)
![AASLD4.gif](../images/111312/111312-6/AASLD4.gif)
![AASLD5.gif](../images/111312/111312-6/AASLD5.gif)
![AASLD6.gif](../images/111312/111312-6/AASLD6.gif)
![AASLD7.gif](../images/111312/111312-6/AASLD7.gif)
![AASLD8.gif](../images/111312/111312-6/AASLD8.gif)
![AASLD9.gif](../images/111312/111312-6/AASLD9.gif)
![AASLD10.gif](../images/111312/111312-6/AASLD10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|